Live attenuated varicella vaccine.
Live attenuated varicella vaccine will in all probability soon be licensed in the United States for immunization of healthy children and adults and certain immunocompromised children. This vaccine can be expected to protect susceptibles from varicella (or to modify it) in those subsequently exposed to the wild virus. The vaccine is safe, immunogenic, and is not associated with an increase in the incidence of zoster.
D000328:Adult; D002644:Chickenpox / Q000517:prevention & control*; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007564:Japan; D014481:United States; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000009:adverse effects; D014765:Viral Vaccines / Q000009:adverse effects
D019433:Chickenpox Vaccine; D014613:Vaccines, Attenuated; D014765:Viral Vaccines